ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Bergenbio Asa

Bergenbio Asa (0RU5)

4.600,00
0,00
(0,00%)
Geschlossen 03 Dezember 5:30PM

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Wichtige Statistiken und Details

Current Price
4.600,00
Gebot
0,00
Fragen
0,00
Volumen
0,00
0,00 Tagesbereich 0,00
4.600,00 52-Wochen-Bereich 4.600,00
Marktkapitalisierung
Handelsende
4.600,00
Handelsbeginn
-
Letzte Trade
(O)
Letzter Handelszeitpunkt
Finanzvolumen
-
VWAP
-
Durchschnittliches Volumen (3 Mio.)
968
Ausgegebene Aktien
2.688.689.000
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
-64.971,75
Gewinn pro Aktie (EPS)
-0,07
Erlöse
354k
Nettogewinn
-190,4M

Über Bergenbio Asa

Sektor
Meas & Controlling Dev, Nec
Branche
Meas & Controlling Dev, Nec
Hauptsitz
Bergen, Nor
Gegründet
-
Bergenbio Asa is listed in the Meas & Controlling Dev sector of the Londoner Börse with ticker 0RU5. The last closing price for Bergenbio Asa was kr4.600,00. Over the last year, Bergenbio Asa shares have traded in a share price range of kr 4.600,00 to kr 4.600,00.

Bergenbio Asa currently has 2.688.689.000 shares in issue. The market capitalisation of Bergenbio Asa is kr12,37 trillion. Bergenbio Asa has a price to earnings ratio (PE ratio) of -64971.75.

0RU5 Neueste Nachrichten

BerGenBio Appoints Olav Hellebø as CEO

BerGenBio Appoints Olav Hellebø as CEO PR Newswire BERGEN, Norway, Nov. 20, 2024 BERGEN, Norway, Nov. 20, 2024 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical...

BerGenBio Appoints Olav Hellebø as CEO

BerGenBio Appoints Olav Hellebø as CEO PR Newswire BERGEN, Norway, Nov. 20, 2024 BERGEN, Norway, Nov. 20, 2024 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical...

BerGenBio announces clinical data presentations highlighting the activity of its selective AXL inhibitor bemcentinib in Non-Small Cell Lung Cancer

BerGenBio announces clinical data presentations highlighting the activity of its selective AXL inhibitor bemcentinib in Non-Small Cell Lung Cancer PR Newswire BERGEN, Norway, Aug. 22, 2023...

BerGenBio announces clinical data presentations highlighting the activity of its selective AXL inhibitor bemcentinib in Non-Small Cell Lung Cancer

BerGenBio announces clinical data presentations highlighting the activity of its selective AXL inhibitor bemcentinib in Non-Small Cell Lung Cancer PR Newswire BERGEN, Norway, Aug. 22, 2023...

BerGenBio ASA: Approval and publication of prospectus for the preferential Rights Issue

BerGenBio ASA: Approval and publication of prospectus for the preferential Rights Issue PR Newswire BERGEN, Norway, May 26, 2023 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR...

BerGenBio ASA: Proposed partially underwritten rights issue

BerGenBio ASA: Proposed partially underwritten rights issue PR Newswire BERGEN, Norway, April 25, 2023 NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES...

BerGenBio Presents Data on STK11 Loss of Function and AXL Activation at AACR

BerGenBio Presents Data on STK11 Loss of Function and AXL Activation at AACR PR Newswire BERGEN, Norway, April 18, 2023 In addition to STK11 mutations, KEAP1m identified as being associated with...

BerGenBio Presents Data on STK11 Loss of Function and AXL Activation at AACR

BerGenBio Presents Data on STK11 Loss of Function and AXL Activation at AACR PR Newswire BERGEN, Norway, April 18, 2023 In addition to STK11 mutations, KEAP1m identified as being associated with...

BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations

BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations PR Newswire BERGEN, Norway, March 9, 2023 - Global...

BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations

BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations PR Newswire BERGEN, Norway, March 9, 2023 - Global...

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10046004600460034814600DE
40046004600460018554600DE
12004600460046009684600DE
26004600460046007794600DE
5200460046004600744614600DE
15600460046004600772624600DE
26000460046004600481304600DE
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
SCGLSealand Capital Galaxy Limited
0,54p
(80,00%)
36,26M
OBDOxford Biodynamics Plc
2,11p
(55,15%)
8,3M
MIRIMirriad Advertising Plc
0,18p
(33,33%)
23,04M
CLCOCloudcoco Group Plc
0,26p
(30,00%)
3,42M
IESInvinity Energy Systems Plc
15,00p
(27,66%)
4,57M
ZNTZentra Group Plc
3,50p
(-36,36%)
221,85k
UOGUnited Oil & Gas Plc
0,125p
(-34,21%)
123,45M
SYSSysgroup Plc
21,50p
(-24,56%)
788,98k
ADAAdams Plc
3,50p
(-22,22%)
25k
DSMDowning Strategic Micro-cap Investment Trust Plc
3,70p
(-21,28%)
22,32k
ORCPOracle Power Plc
0,0525p
(-7,89%)
3,65B
NTVONativo Resources Plc
0,0023p
(-8,00%)
1,51B
SYMESupply@me Capital Plc
0,0031p
(-10,14%)
1,11B
KEFIKefi Gold And Copper Plc
0,524p
(-19,63%)
567,23M
ENETEthernity Networks Ltd
0,1425p
(18,75%)
551,92M
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

Delayed Upgrade Clock